Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Carcinoma, Hepatocellular × orantinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 1

Interventions

Sorafenib 49 pembrolizumab 20 Nivolumab 18 Bevacizumab 16 Radiosurgery 15 Doxorubicin 12 lenvatinib 8 Erlotinib Hydrochloride 7 atezolizumab 6 Ramucirumab 6 Magnetic Resonance Spectroscopy 6 Cisplatin 6 tremelimumab 5 durvalumab 5 cabozantinib 5 Radiofrequency Ablation 5 tislelizumab 4 Sunitinib 4 Ipilimumab 4 regorafenib 3 nintedanib 3 carotuximab 3 bavituximab 3 Ribavirin 3 Radiotherapy 3 Oxaliplatin 3 Mitomycin 3 Leucovorin 3 Fluorouracil 3 Everolimus 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01465464 2019-08-07

ORIENTAL

Taiho Pharmaceutical Co., Ltd.

Phase 3 Terminated

888 enrolled 12 charts

Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡